

IDS/ #10
3/13/02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Thomas Teufel	Examiner:	Unassigned
Serial No.:	Unassigned	Group Art Unit:	Unassigned
Filed:	Herewith	Docket:	381-86
For:	TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS	Dated:	August 9, 2000

1c841 U.S. PTO
09/635974
08/09/00

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.*

20231 on August 9, 2000

Dated: 8/9/2000

J. Peterson

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.
§1.56, Applicants submit herewith the following Information Disclosure Statement in
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

UNITED STATES PATENTS

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Boss et al.	4,816,397	March 28, 1989
Levitzki et al.	5,196,446	March 23, 1993
Strayer	5,550,114	August 27, 1996
Spada et al.	5,646,153	July 8, 1997

Spada et al.	5,656,655	August 12, 1997
Bridges et al.	5,679,683	October 21, 1997
Chen et al.	5,789,427	August 4, 1998
Ullrich et al.	5,851,999	December 22, 1998
Rockwell et al.	5,861,499	January 19, 1999
Morgan, Jr. et al.	5,869,465	February 9, 1999
Bennett et al.	5,914,269	June 22, 1999
Davis et al.	5,925,566	July 20, 1999
Rockwell et al.	5,955,311	September 21, 1999
McMahon et al.	6,004,967	December 21, 1999

FOREIGN PATENT DOCUMENTS

<u>COUNTRY</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Europe	PCT/AU99/00420	May 31, 1999

NON-PATENT PUBLICATIONS


1. Green, Larry L, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," *Journal of Immunological Methods*, # 231:11-23 (1999).
2. Jost, et al., "A Central Role of Bcl-X_L in the Regulation of Keratinocyte Survival by Autocrine EGFR Ligands," *The Journal of Investigative Dermatology*, # 112:443-449 (1999).
3. Kao, et al., "Comparison of the Effect of 8-Methoxypsoralen (8-MOP) plus UVA (PUVA) on Human Melanocytes in Vitiligo Vulgaris and *In Vitro*," *The Journal of Investigative Dermatology*, # 98(5):734-740 (1992).

4. Rikimaru, et al., "Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture," *Experimental Dermatology*, #6:214-221 (1997).
5. Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and Hyperproliferative Human Keratinocytes," *Brief Definitive Report*, # 167:670-675 (1998).
6. Fransson et al., "Epidermal growth in the skin equivalent," *Archives of Dermatological Research*, # 284:343-348 (1992).
7. Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," *Journal of the American Academy of Dermatology*, # 40:901-9 (1999).
8. Varani, et al., "Human Psoriatic Skin in Organ Culture: Comparison with Normal Skin Exposed to Exogenous Growth Factors and Effects of an Antibody to the EGF Receptor," *Pathobiology*, # 66:253-259 (1998).
9. Elder, et al., "Human Severe Combined Immunodeficiency Due to a Defect in ZAP-70, a T Cell Tyrosine Kinase," *Science*, # 264: (1994).
10. Dvir, et al., "The Inhibition of EGF-dependent Proliferation of Keratinocytes by Tyrphostin Tyrosin Kinase Blockers," *The Journal of Cell Biology*, # 113:4 (1991).
11. Grossman, et al., "Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes," *Proc. Natl. Acad. Sci. USA*, # 86:6367-6371 (1989).
12. Fry, et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," *Science*, # 265:1093-1095 (1994).
13. Vassar, et al., "Transgenic mice provide new insights into the role of TGF- α during epidermal development and differentiation," *Genes & Development*, # 5:714-727 (1991).
14. Gazit, et al., "Tyrphostins. 6. Dimeric Benzyldenemalononitrile Tyrphostins: Potent Inhibitors of EGF Receptor Tyrosine Kinase *in Vitro*," *Journal of Medicinal Chemistry*, # 39:4905-4911 (1996).
15. Ben-Bassat, et al., "Tyrphostins suppress the growth of psoriatic keratinocytes," *Experimental Dermatology*, # 4:82-88 (1995).
16. Panek, et al., "In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor," *The Journal of Pharmacology and Experimental Therapeutics*, # 283 (3):1433-1444 (1997).
17. Abgenix, Inc. Press Release, "Abgenix Initites Phase III Clinical Trial with ABX-IL8 in Psoriasis," April 3, 2000.

The above-referenced documents are listed on PTO Form 1449. Copies of the cited documents are enclosed to facilitate reference to them.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,


James F. Harrington
Registration No.: 44,741
Attorney for Applicant

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
JFH/jp

115479_1.DOC

Docket Number: 381-86



TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH
EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS

Invented by:
Thomas Teufel

Patent Application Prepared By: James F. Harrington
Registration No. 44,741
HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550